What the new NSW injectables rules mean for nurses
From 5 November 2026, the rules for administering cosmetic injectables in NSW change. The reassuring part: most of what is changing simply takes good practice that Fresh members are already following and writes it into law.
If you work with Fresh, you are already covered. The review, the sign-off, the records and the storage are all built into how you work with us. We have read the new regulation and pulled out what it actually means for you, in plain language.
First, what products this covers
The new rules apply to eight prescription-only substances when they are used cosmetically:
• botulinum toxins
• calcium hydroxylapatite
• collagen
• deoxycholic acid
• hyaluronic acid and its polymers
• polyacrylamide
• polycaprolactone
• polylactic acid
If you administer any of these, everything below applies to you.
You need written direction from your prescriber, based on a real review
You can only inject one of these substances when your prescriber has authorised it for that specific patient. For that direction to count, the prescribing doctor or nurse practitioner has to have personally reviewed the patient, either in person or over video, then put the authorisation in writing and sign it. It lasts up to 6 months from the review date, so a regular patient needs reviewing again at least every 6 months.
None of this should feel new. The 6-month cadence is consistent with NSW requirements. What has changed is that this is now written into law. A tick-box script for a patient the prescriber has never seen does not meet the bar.
If you work with Fresh: no change for you. The review, the sign-off and the 6-month cycle are already built into how the app works.
The product has to be legitimate
The substance you inject has to be properly registered. That means it is either on the Australian Register of Therapeutic Goods (ARTG), approved for supply under section 19 or 19A of the Commonwealth Therapeutic Goods Act, or supplied by a manufacturer that holds a Commonwealth manufacturing licence.
Here is the part that matters most for you. The rules put that check on both the nurse and the prescriber. If you cannot confirm where a product came from and that it is properly registered, that is now your risk too.
This measure is aimed at unlawful sourcing practices that exist in parts of the industry. Fresh supports this effort to protect patients and the public, as we are sure you do too.
If you work with Fresh: this is exactly why requesting and supplying product through Fresh matters. When product comes through Fresh's medical oversight, you have a full trail of where it came from, so confirming it is legitimate is not something you have to chase down yourself.
Vial sharing, cleared up
An earlier draft of this reform, released for consultation in early 2026, proposed more restrictive rules around administering from a single vial across more than one patient. That specific restriction was not carried through into the final regulation as made.
What the final regulation does require is clear record-keeping for every administration. Each one must be documented with the patient's name, date, and batch number, and tied back to the specific direction it relates to. Please make sure your own record-keeping reflects this standard.
A written record for every single treatment
For each administration, you make a written record that includes your name, the date, the batch number of the substance, and the patient and treatment details from the sign-off. You then give a copy to the prescriber and to the clinic.
If you work with Fresh: this will be managed in your drugbook and will be ready to use in alignment with the regulatory roll out.
Emergency equipment, training and storage are now legal requirements
Three things that were good practice are now written into law:
• appropriate equipment has to be on hand for a patient medical emergency
• every nurse administering has to be adequately trained for a medical emergency
• product has to be stored securely, away from public access and food, and in line with the label
If you work with Fresh: none of this should be a surprise. It is already in line with Fresh's clinical standards.
The clinic carries responsibility too
It is not all on the nurse. The clinic or business administering these substances now carries its own duties: making sure treatments are done properly, that emergency equipment and training are in place, and that copies of every sign-off and every record are kept. Responsibility is shared across you, your prescriber, and the clinic.
What sits behind the rules
Because this is now law rather than guidance, there are penalties attached. For the most serious requirements, an individual can face a fine of up to $22,000. For the record-keeping and storage requirements, up to $5,500.
The point is not to alarm anyone. It is a signal that what was best practice, now matters more than ever: a real and tracked patient review, a valid sign-off, legitimate product, and a clear record for every treatment.
Where we sit on this
If you're already working properly with your prescriber and keeping thorough records, this doesn't change anything for you. November's changes are already part of Fresh clinical standards.
If you are not set up this way yet, there is time to get the basics in place before the rules start. Either way, we are across this and here to help.
This is a plain-language summary of the cosmetic injectables rules in Part 9 of the Medicines, Poisons and Therapeutic Goods Regulation 2026 (NSW), which commences on 5 November 2026. It is general information, not legal advice.
CONTACT US
Clinic marketing in 2026: what to do when you can't directly market your services
Why your rebook rate matters more than your pricing (and how one Fresh Member built 88% retention)
